The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

The global lung cancer therapeutics market is on a robust growth trajectory, poised to witness a significant transformation over the next decade. According to recent market projections, the industry ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

25, 2025 — In recent years, cell ... treatment and mortality from data on over 500,000 lung cancer patients. This study suggests that immunotherapy may not be the optimal ... New, Rare Type of ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...